Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

Life After Treatment: Surveillance and Survivorship

At a Glance

After MPNST treatment, patients require at least 10 years of close surveillance to monitor for recurrence. This typically involves chest CT scans to check the lungs and MRIs of the original tumor site, scheduled every 3 to 6 months initially and tapering to annually.

Completing primary treatment for Malignant Peripheral Nerve Sheath Tumor (MPNST) is a major milestone, but it also marks the beginning of a long-term commitment to surveillance [1]. Because MPNST is aggressive and has a high risk of returning locally or spreading to other organs, your doctors will monitor you closely for at least 10 years [2][3].

The Importance of Lung Surveillance

The lungs are the most common site for MPNST to spread (metastasis) [4]. Early detection of a small spot on the lung is critical because it may be treatable with surgery.

  • Chest CT vs. X-ray: While a chest X-ray is faster and uses less radiation, a Chest CT scan is much more sensitive at finding tiny nodules that an X-ray might miss [5]. Many sarcoma centers prefer a “low-dose” CT for routine monitoring [6].
  • Local Monitoring: You will also need regular MRIs of the original tumor site to check for local recurrence—the cancer returning in the same spot [1][7].

A Typical Surveillance Schedule

While every plan is personalized, the NCCN and ESMO guidelines generally follow a schedule based on the risk of the tumor returning [3]:

Years Post-Treatment Frequency of Scans (Chest & Local Site)
Years 1 – 2 Every 3 to 6 months [3]
Years 3 – 5 Every 6 months [3]
Years 5 – 10 Annually (once per year) [3]

The Role of PET/CT

A PET/CT scan is generally not used for every check-up. Instead, it is a powerful tool used when [8][9]:

  • Other scans (like an MRI) show something suspicious that needs further investigation.
  • A patient has new symptoms, but standard scans aren’t showing the cause.
  • The doctor needs to “re-stage” the cancer to see if it has moved to other parts of the body.

Managing “Scanxiety”

It is very common to feel intense worry in the days or weeks leading up to a follow-up appointment—a phenomenon often called scanxiety [10]. About 45% of sarcoma patients experience significant psychological distress at some point [11].

  • Coping Strategies: Techniques like mindfulness, focusing on the present moment, and Cognitive Behavioral Therapy (CBT) have been shown to help patients manage this stress [12][13].
  • Support Systems: Many specialized centers have psychosocial oncology teams. Asking for a referral to a counselor who understands cancer-related trauma can significantly improve your quality of life during survivorship [14][15]. Connecting with advocacy organizations, such as the Children’s Tumor Foundation (for NF1) or the Sarcoma Foundation of America, can provide invaluable peer support from people who truly understand what you are going through [12].

When to Call Your Doctor

Between scheduled scans, you should contact your care team immediately if you notice:

  1. New lumps or bumps at or near the original surgical site.
  2. Unexplained pain that is persistent or worsening.
  3. A persistent cough or shortness of breath.
  4. New neurological symptoms, such as weakness, numbness, or “pins and needles” [16][17].

Common questions in this guide

What is the typical follow-up scan schedule after MPNST treatment?
For the first two years, scans are typically done every 3 to 6 months. From years three to five, scans occur every 6 months, and then taper to once a year for up to 10 years post-treatment.
Why do I need chest CT scans during my follow-up appointments?
The lungs are the most common area where MPNST can spread. A chest CT scan is highly sensitive and can detect tiny nodules or early signs of spread much better than a standard chest X-ray.
When is a PET scan used during MPNST surveillance?
A PET/CT scan is not typically used for routine check-ups. Doctors order it when standard scans show something suspicious, you develop new unexplained symptoms, or they need to confirm if the cancer has spread.
What symptoms should I report to my doctor between scheduled scans?
Contact your care team immediately if you develop new lumps near the original surgery site, unexplained or worsening pain, a persistent cough, or new neurological symptoms like numbness or weakness.
How can I manage my anxiety before follow-up scans?
Many patients experience intense worry before follow-ups. Techniques like mindfulness and Cognitive Behavioral Therapy (CBT) are very effective. You can also ask your center for a referral to a psychosocial oncology counselor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor grade and surgical margins, what is my specific schedule for scans over the next five years?
  2. 2.Will we be using chest CT or chest X-rays to monitor my lungs, and why?
  3. 3.Under what circumstances would you order a PET/CT instead of a standard MRI or CT?
  4. 4.What 'red flag' symptoms should I look for that would warrant a scan earlier than my scheduled appointment?
  5. 5.Can you recommend any resources or specialists to help me manage the anxiety I feel before my follow-up scans?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Clinicopathological study of malignant peripheral nerve sheath tumors in the head and neck: Case reports and review of literature.

    Li L, Ma XK, Gao Y, et al.

    World journal of clinical cases 2023; (11(25)):5910-5918 doi:10.12998/wjcc.v11.i25.5910.

    PMID: 37727493
  2. 2

    Malignant peripheral nerve sheath tumor with extensive osteosarcomatous and chondrosarcomatous differentiation: A case report.

    Meshikhes AW, Duhaileb MA, Amr SS

    International journal of surgery case reports 2016; (25()):188-91.

    PMID: 27388706
  3. 3

    Late Local Recurrence and Metastasis in Soft Tissue Sarcoma of the Extremities and Trunk Wall: Better Outcome After Treatment of Late Events Compared with Early.

    von Konow A, Ghanei I, Styring E, Vult von Steyern F

    Annals of surgical oncology 2021; (28(12)):7891-7902 doi:10.1245/s10434-021-09942-8.

    PMID: 33861406
  4. 4

    Malignant Peripheral Nerve Sheath Tumor of the Cervix.

    Zhang T, Wang Z, Wang R, et al.

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2022; (32(4)):S24-S27 doi:10.29271/jcpsp.2022.Supp1.S24.

    PMID: 35633002
  5. 5

    Osteosarcoma follow-up: chest X-ray or computed tomography?

    Paioli A, Rocca M, Cevolani L, et al.

    Clinical sarcoma research 2017; (7()):3 doi:10.1186/s13569-017-0067-5.

    PMID: 28228934
  6. 6

    Ultra-low-dose computed tomography and chest X-ray in follow-up of high-grade soft tissue sarcoma-a prospective comparative study.

    Salminen S, Jäämaa S, Nevala R, et al.

    Scientific reports 2024; (14(1)):7181 doi:10.1038/s41598-024-57770-z.

    PMID: 38531939
  7. 7

    Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.

    Salamon J, Mautner VF, Adam G, Derlin T

    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2015; (187(12)):1084-92 doi:10.1055/s-0035-1553505.

    PMID: 26333104
  8. 8

    18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Postsurgical Setting in Head and Neck Cancers - A Pictorial Essay.

    Agrawal A, Prakash A, Choudhury S, et al.

    Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2021; (36(2)):195-200 doi:10.4103/ijnm.ijnm_204_20.

    PMID: 34385794
  9. 9

    Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

    Vaz SC, Woll JPP, Cardoso F, et al.

    European journal of nuclear medicine and molecular imaging 2024; (51(9)):2706-2732 doi:10.1007/s00259-024-06696-9.

    PMID: 38740576
  10. 10

    Scanxiety and Fear of Recurrence in Young Adult Female Breast and Gynaecological Cancer Survivors: Investigating Shared Mechanisms.

    Patel DS, Webster SN, Dowling EJ, et al.

    Psycho-oncology 2024; (33(12)):e70050 doi:10.1002/pon.70050.

    PMID: 39694862
  11. 11

    Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience.

    Srikanthan A, Leung B, Shokoohi A, et al.

    Sarcoma 2019; (2019()):5302639 doi:10.1155/2019/5302639.

    PMID: 31354383
  12. 12

    Are digital psychological interventions for psychological distress and quality of life in cancer patients effective? A systematic review and network meta-analysis.

    Zhang T, Ren Z, Wakefield CE, et al.

    Clinical psychology review 2025; (115()):102520 doi:10.1016/j.cpr.2024.102520.

    PMID: 39615074
  13. 13

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  14. 14

    Psychosocial distress and associated factors among adult cancer patients at oncology: a case of Ethiopia.

    Baye AA, Bogale SK, Delie AT, et al.

    Frontiers in oncology 2023; (13()):1238002 doi:10.3389/fonc.2023.1238002.

    PMID: 38192622
  15. 15

    Effectiveness of Internet-Based Cognitive Behavioral Therapy for Patients With Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

    Yu S, Liu Y, Cao M, et al.

    Cancer nursing 2025; (48(3)):e140-e149 doi:10.1097/NCC.0000000000001274.

    PMID: 37552227
  16. 16

    Malignant Peripheral Nerve Sheath Tumor Arising Within Lumbar Spinal Plexiform Neurofibroma.

    Alves Júnior SF, Pessoa Corrêa JA, Marchiori E

    World neurosurgery 2019; (130()):264-266 doi:10.1016/j.wneu.2019.07.085.

    PMID: 31323411
  17. 17

    Giant intrapelvic malignant peripheral nerve sheath tumor mimicking disc herniation: A case report.

    Wang P, Chen C, Xin X, et al.

    Molecular and clinical oncology 2016; (5(5)):653-656 doi:10.3892/mco.2016.1030.

    PMID: 27900106

This page provides educational information on MPNST survivorship and post-treatment surveillance. Always consult your oncology team for your personalized follow-up schedule and medical advice.

Get notified when new evidence is published on Malignant peripheral nerve sheath tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.